The estimated Net Worth of Daniel L Weiner is at least $1.19 Milione dollars as of 28 June 2024. Daniel Weiner owns over 750 units of Simulations Plus stock worth over $229,965 and over the last 7 years he sold SLP stock worth over $766,443. In addition, he makes $193,867 as Independent Director at Simulations Plus.
Daniel has made over 5 trades of the Simulations Plus stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 750 units of SLP stock worth $36,990 on 28 June 2024.
The largest trade he's ever made was selling 5,217 units of Simulations Plus stock on 2 February 2021 worth over $422,055. On average, Daniel trades about 450 units every 34 days since 2017. As of 28 June 2024 he still owns at least 7,009 units of Simulations Plus stock.
You can see the complete history of Daniel Weiner stock trades at the bottom of the page.
Dr. Daniel L. Weiner Ph.D. serves as Independent Director of the Company. He has extensive drug development experience and has served as an expert consultant to the U.S. Food and Drug Administration (FDA) on pharmacokinetic modeling and bioequivalence assessment. Prior to his previous tenure with Certara/Pharsight as a Senior Vice President and Chief Science Officer, Dr. Weiner held several management positions with Merrell Dow Pharmaceuticals; Statistical Consultants, Inc.; Syntex Development Research; Quintiles; and IVAX Research. Dr. Weiner graduated from the University of Kentucky with a doctoral degree in Mathematical Statistics, with emphasis on compartmental modeling. He is the original designer/author of the WinNonlin family of PK/PD Modeling Software now used by over 1,000 institutions. He is the co-author of Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, now in its fifth edition. Dr. Weiner is an Adjunct Associate Professor with the Division of Pharmacotherapy and Experimental Therapeutics in the School of Pharmacy, University of North Carolina, and an Affiliate Professor of Pharmacometrics, Center for Translational Medicine in the School of Pharmacy at the University of Maryland.
As the Independent Director of Simulations Plus, the total compensation of Daniel Weiner at Simulations Plus is $193,867. There are 11 executives at Simulations Plus getting paid more, with Shawn M. O'Connor having the highest compensation of $544,231.
Daniel Weiner is 70, he's been the Independent Director of Simulations Plus since 2017. There are 3 older and 11 younger executives at Simulations Plus. The oldest executive at Simulations Plus Inc. is Walter S. Woltosz M.A.S., M.S., 76, who is the Co-Founder & Chairman.
Daniel's mailing address filed with the SEC is 42505, 10th Street West, Lancaster, California, 93534, United States.
Over the last 21 years, insiders at Simulations Plus have traded over $70,055,940 worth of Simulations Plus stock and bought 24,000 units worth $1,395,840 . The most active insiders traders include Walter Swoltosz Virginia E ..., Walter S Woltosz e Momoko A Beran. On average, Simulations Plus executives and independent directors trade stock every 37 days with the average trade being worth of $571,025. The most recent stock trade was executed by Jill Fiedler Kelly on 9 September 2024, trading 2,250 units of SLP stock currently worth $21,848.
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
Simulations Plus executives and other stock owners filed with the SEC include: